Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice

Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice

Abstract Background Edaravone-Dexborneol (EDB) presents therapeutic effects due to its anti-inflammatory, antioxidant and anti-apoptotic properties, and has been widely used in ischemic stroke. However, the detailed efficacy and potential target of EDB in Alzheimer’s disease (AD) are still elusive....

Full description

Saved in:
Bibliographic Details
Main Authors: Rui Mao, Shu Shu, Min Sun, Jiang Chen, Mengsha Hu, Lei Ye, Siyi Xu, Junqiu Jia, Wenxuan Shao, Xinyu Bao, Yun Xu, Xiaolei Zhu
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer's disease
Edaravone-Dexborneol
β-amyloid
Oxidative stress
Neuroinflammation
S100A9
Online Access:https://doi.org/10.1186/s13195-025-01777-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13195-025-01777-9

Similar Items